BeiGene (HKG:6160, SHA:688235) is proposing to change its English name to BeOne Medicines, while keeping its Chinese name unchanged, a Thursday bourse filing said.
The proposal comes about in order to reaffirm the drugmaker's commitment to develop innovative medicines to eliminate cancer by partnering with the global community and treat as many patients as possible.
The name change is subject to shareholder and regulatory approvals.
Hong Kong-listed shares of the company closed over 3% lower on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments